<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130546</url>
  </required_header>
  <id_info>
    <org_study_id>FreRace-Study 186/02</org_study_id>
    <nct_id>NCT00130546</nct_id>
  </id_info>
  <brief_title>Intra-Individual Comparison of Sirolimus and Paclitaxel Coated Stent (FRE-RACE Study)</brief_title>
  <official_title>A Prospective, Randomized Intra-Individual Study With the Sirolimus Coated Cypher Select(TM) and the Paclitaxel(TM) Coated Express Balloon Expandable Stents for the Treatment of Patients With Two de Novo Native Coronary Artery Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cordis Medizinische Apparate GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and effectiveness of the Sirolimus&#xD;
      eluting Cypher Select(TM) stent in reducing angiographic in-stent late loss in de novo native&#xD;
      coronary lesions as compared to the TAXUS(TM) Paclitaxel-eluting stent in patients presenting&#xD;
      with two or more coronary artery stenoses (prospective, randomized, intra-individual&#xD;
      comparison).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, 2 arm, randomized, multicenter Phase III study (6 centers).&#xD;
&#xD;
      A total of 110 patients with at least two de novo native coronary artery lesions (lesion A,&#xD;
      lesion B) ≤ 30 mm in length and ≥ 2.25 mm to &lt; 3.0 mm in diameter by visual estimate will be&#xD;
      enrolled. Patients will be randomized for implantation of the sirolimus eluting Cypher&#xD;
      Select(TM) Balloon-Expandable Stent or to the TAXUS(TM) Paclitaxel-eluting stent for lesion A&#xD;
      and B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is angiographic in-stent late loss at 8-months follow-up as determined by quantitative coronary angiography</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion and vessel revascularization (TLR, TVR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE) at 30 days, 8 and 12 months</measure>
    <time_frame>30 days, 8 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cypher Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taxus Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel-eluting TAXUS(TM)</intervention_name>
    <description>TAXUS(TM) Paclitaxel-eluting stent</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus eluting Cypher Select(TM)</intervention_name>
    <description>Sirolimus eluting Cypher Select(TM) stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must be &gt;=18 and &lt;=85 years of age&#xD;
&#xD;
          -  Female of childbearing potential must have a negative pregnancy test at the time of&#xD;
             enrolment and utilize reliable birth control for the duration of their participation&#xD;
             in the trial&#xD;
&#xD;
          -  Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society&#xD;
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald&#xD;
             Classification B&amp;C, I-II-III) and documented ischemia OR patients with documented&#xD;
             silent ischemia&#xD;
&#xD;
          -  Two or more de novo lesions &lt; 30 mm in length (visual estimate)&#xD;
&#xD;
          -  Target vessel at lesion site is ≥ 2.25 mm and ≤ 3.0 mm in diameter (visual estimate)&#xD;
&#xD;
          -  Target lesion is located in a native coronary artery which can be covered by one stent&#xD;
             (single lesion)&#xD;
&#xD;
          -  Acceptable candidate for coronary artery bypass surgery (CABG)&#xD;
&#xD;
          -  Target lesion stenosis is &gt; 50% and &lt; 100% (thrombolysis in myocardial infarction&#xD;
             [TIMI] 1) (visual estimate)&#xD;
&#xD;
          -  Target lesions do not differ in length for more than 6 mm&#xD;
&#xD;
          -  Patient is willing to comply with the specified follow-up evaluation&#xD;
&#xD;
          -  Patient must provide written informed consent prior to the procedure using a form that&#xD;
             is approved by the local Ethics Committee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Q-wave or non-Q-wave myocardial infarction within the preceding 72 hours unless the CK&#xD;
             and CK-MB enzymes are back to normal&#xD;
&#xD;
          -  Unprotected left main coronary disease with &gt;= 50% stenosis&#xD;
&#xD;
          -  Impaired runoff in the treatment vessel with diffuse distal disease&#xD;
&#xD;
          -  Ostial target lesion&#xD;
&#xD;
          -  Angiographic evidence of thrombus within target lesion&#xD;
&#xD;
          -  Calcified lesions which cannot be successfully predilated&#xD;
&#xD;
          -  Ejection fraction &lt;= 30%&#xD;
&#xD;
          -  Totally occluded vessel (TIMI 0 level)&#xD;
&#xD;
          -  Impaired renal function (creatinine &gt; 3.0 mg/dl)&#xD;
&#xD;
          -  Pretreatment with devices other than balloon angioplasty&#xD;
&#xD;
          -  Target lesion has excessive tortuosity unsuitable for stent delivery and deployment&#xD;
&#xD;
          -  Target lesion involves bifurcation including a side branch &gt;= 2.5 mm in diameter&#xD;
             (either stenosis of both main vessel and major branch or stenosis of just major&#xD;
             branch) that would require side branch stenting which is likely to occur if side&#xD;
             branch is diseased and intended to be stented&#xD;
&#xD;
          -  Prior stent within 5 mm of target lesion this includes in-stent restenosis&#xD;
&#xD;
          -  Significant (&gt; 50%) untreated stenoses proximal or distal to the target lesion that&#xD;
             will not be treated during the procedure and may require revascularization or impede&#xD;
             runoff&#xD;
&#xD;
          -  Intervention of another lesion has occurred within one month before or is planned or&#xD;
             highly probable to be performed within the next 30 days after this index procedure&#xD;
&#xD;
          -  Recipient of heart transplant&#xD;
&#xD;
          -  Patient with a life expectancy less than 12 months&#xD;
&#xD;
          -  Known allergies to aspirin, clopidogrel bisulfate (Plavix®), ticlopidine (Ticlid®),&#xD;
             heparin stainless steel, contrast agent, Paclitaxel or Sirolimus&#xD;
&#xD;
          -  Any significant medical condition which in the investigator's opinion may interfere&#xD;
             with the patient's optimal participation in the study&#xD;
&#xD;
          -  Target lesion located in an arterial or venous by-pass graft&#xD;
&#xD;
          -  Currently participating in an investigational drug or another device study&#xD;
&#xD;
          -  Unstable angina pectoris Braunwald Classification A I-II-III or is having a&#xD;
             peri-infarction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Zehender, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert-Ludwig University Clinic</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <study_first_submitted>August 11, 2005</study_first_submitted>
  <study_first_submitted_qc>August 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <last_update_submitted>May 14, 2009</last_update_submitted>
  <last_update_submitted_qc>May 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Zehender</name_title>
    <organization>University Hospital Freiburg</organization>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>coronary intervention</keyword>
  <keyword>drug eluting stent implantation</keyword>
  <keyword>Cypher - Stent</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Taxus - Stent</keyword>
  <keyword>Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

